Farmacy

Aug 24 2017

Transtech pharma #biotechnology

#transtech pharma # Overview Glucagon-like peptide-1 (GLP-1) is a member of the incretin family of neuroendocrine peptide hormones secreted from L-cells of the intestine in response to food ingestion. GLP-1 has multiple metabolic effects that are attractive for an anti-diabetic agent. A key function of GLP-1 is to activate its receptor, GLP-1R, on the pancreatic β-cell to enhance glucose-dependent insulin secretion. Additional positive metabolic benefits of GLP-1 include suppression of excessive glucagon production, decreased food intake, delayed gastric emptying and improvement of β-cell mass and function. Unfortunately, the rapid proteolysis of GLP-1 in blood limits its use as a therapeutic …

Aug 24 2017

TransTech Pharma, Inc #pharma #market #access

#transtech pharma # High Point, North Carolina (January 25, 2008) High Point, NC and Bagsvaerd, Denmark – January 25, 2008 – TransTech Pharma, Inc. and Novo Nordisk A/S announced today that TransTech has acquired all rights from Novo Nordisk to a portfolio of drug candidates being developed to treat metabolic disorders. This portfolio is comprised of three distinct therapeutic approaches to such treatment: H3 receptor antagonists, PPARd agonists, and 11βHSD1 inhibitors. After determining in January 2007 to focus all Novo Nordisk research and development resources on the company’s growing pipeline of protein-based pharmaceuticals, the company divested all existing preclinical and …

Aug 13 2017

Transtech pharma #pharma #database

#transtech pharma # Overview Glucagon-like peptide-1 (GLP-1) is a member of the incretin family of neuroendocrine peptide hormones secreted from L-cells of the intestine in response to food ingestion. GLP-1 has multiple metabolic effects that are attractive for an anti-diabetic agent. A key function of GLP-1 is to activate its receptor, GLP-1R, on the pancreatic β-cell to enhance glucose-dependent insulin secretion. Additional positive metabolic benefits of GLP-1 include suppression of excessive glucagon production, decreased food intake, delayed gastric emptying and improvement of β-cell mass and function. Unfortunately, the rapid proteolysis of GLP-1 in blood limits its use as a therapeutic …

Aug 13 2017

TransTech Pharma and Calithera Biosciences Enter Into Worldwide Licensing Agreement for Hexokinase II Inhibitor Program

#transtech pharma # TransTech Pharma and Calithera Biosciences Enter Into Worldwide Licensing Agreement for Hexokinase II Inhibitor Program March 05, 2015 04:03 PM Eastern Standard Time HIGH POINT, N.C.–( BUSINESS WIRE )–TransTech Pharma, LLC today announced a global licensing agreement granting Calithera Biosciences, Inc. exclusive world-wide rights to research, develop and commercialize TransTech’s portfolio of hexokinase II inhibitors. TransTech will receive an upfront payment and will be eligible to receive future development and commercialization milestones as well as royalties on sales of approved products. Hexokinase II is the first enzyme in the pathway that enables cancer cells to convert glucose …